Large artery stiffening is increased in advanced chronic kidney disease (CKD) and is thought to causally mediate various cardiovascular complications of CKD. Carotid-femoral pulse wave velocity (CF-PWV), the noninvasive gold-standard measure of large artery stiffness, is strongly associated with increased mortality in advanced CKD. However, large artery stiffening and calcification likely develop progressively in earlier stages of CKD. The identification of pathways related to arterial stiffness in earlier CKD stages may provide opportunities for novel therapeutic strategies to ameliorate the arterial stiffness and calcification process in CKD.
METHODS
We prospectively enrolled a convenience sample of 137 adults at the Corporal Michael J. Crescenz VA Medical Center. The protocol was approved by the Philadelphia VA Medical Center Institutional Review Board, and all subjects provided written informed consent. We included subjects aged >18 years who were referred to our Department for a cardiac imaging study. Key exclusion criteria were as follows: (i) conditions that could make the measurements of CF-PWV less accurate and/or unreliable (i.e., arrhythmia such as atrial fibrillation), (ii) heart failure with reduced or preserved ejection fraction.
Subjects were stratified according to estimated glomerular filtration rate (eGFR), as follows: normal GFR (>90 ml/min; n = 59), mildly reduced GFR (stage 2 CKD: GFR = 60-89 ml/ min; n = 53), or at least moderately reduced GFR (stage 3-5 CKD; GFR < 60 ml/min; n = 25). GFR was estimated using the creatinine-based CKD-Epidemiology equation.
CF-PWV measurement
CF-PWV, considered the noninvasive "gold-standard" index of large artery stiffness, 5, 6 was measured using the SphygmoCor system. Briefly, carotid-to-femoral transit time (ΔT) was computed from the foot-to-foot time difference between sequentially acquired carotid and femoral waveforms, using the intersecting tangents method, and the QRS complex of the ECG as a fiducial point. The distance between the sternal notch and the carotid artery was subtracted from the distance between the sternal notch and the femoral artery, in order to estimate the path length (L), and CF-PWV was computed as L/ΔT.
Plasma dp-ucMGP measurement Citrate tubes were used for collection of venous blood sample at the time of enrollment. The plasma was prepared and stored at −80 °C for batch analysis. A dual-antibody sandwich enzyme-linked immunosorbent assay (ELISA) technique (VitaK; Maastricht University; The Netherlands) was used to measure dp-ucMGP. Intra-assay coefficients of variation for this assay have previously been reported at 3.1% and 5.4% for lower and upper limit of normal. Interassay variation coefficients are 6.9% and 13.6% for lower and upper limits of normal. 2 
Statistical methods
Continuous and categorical variables were compared between the groups using analysis of variance (ANOVA) and chi-square tests, respectively. Post-hoc analysis was conducted using the Bonferroni correction method. Bivariate and multivariate linear regression models were utilized to assess dp-ucMGP as a predictor of CF-PWV. When required, Box-Cox transformation was applied to normalize regression model residuals. We present standardized regression coefficients for easier comparison of the magnitude of the effect of various predictors on the dependent variable in regression models. All tests were 2-tailed. Statistical significance was defined as an alpha value ≤0.05.
We also performed formal statistical mediation analyses 7 when appropriate to assess whether dp-ucMGP mediates a relationship between eGFR and CF-PWV. Mediating variables are "intermediate" factors that act as a link between a dependent variable and an independent variable. Mediation analyses quantify direct and indirect effect sizes that contribute to an observed relationship between the independent variable (in this case, eGFR) and a dependent variable (in this case, CF-PWV) and examine the role of the potential statistical mediator (in this case, dp-ucMGP). 7 Estimates of the total, direct, and indirect effect size were computed. Significant mediation is established when the indirect effect is significantly different from zero. Standardized regression coefficients and effect sizes are presented for easier comparison of the magnitude of the relationships of different predictors. All probability values are 2-tailed. Statistical significance was defined as a 2-tailed P value <0.05. We used SPSS v24 for Mac (IBM, Chicago, IL), the Statistics and Machine Learning Toolbox and the M3 mediation toolbox 8, 9 within Matlab v2016b (The Mathworks; Natick, MA). Table 1 shows the general characteristics of the study samples stratified by eGFR. The majority of the sample was composed of males. Subjects with eGFR between 60 and 89 and <60 ml/min/1.73 m 2 were significantly older than those with eGFR ≥90 ml/min/1.73 m 2 . African Americans comprised more than half of the group with eGFR >90 ml/ min/1.73 m 2 but only one-third of the groups with eGFRs of 60-89 ml/min/1.73 m 2 and <60 ml/min/1.73 m 2 . Subjects with eGFR <60 ml/min/1.73 m 2 had the highest prevalence of comorbidities such as hypertension (92%) and diabetes mellitus (68%). Furosemide, aspirin, beta blocker, and warfarin were more commonly used by subjects with eGFR <90 ml/min/1.73 m 2 . There was a trend for increasing CF-PWV with decreasing kidney function. Magnesium levels were lower in subjects with eGFR <60 compared to those with eGFR ≥90 ml/min/1.73 m 2 , with a trend for lower calcium and higher phosphate levels with decreasing eGFR.
RESULTS

Dp-ucMGP levels and renal function
Unadjusted and adjusted comparisons of dp-ucMGP levels between subjects with normal renal function, mildly reduced eGFR, and at least moderately reduced eGFR are shown in Figure 1 and Table 2 .
Plasma dp-ucMGP was progressively higher with decreasing renal function (GFR ≥ 90: 247 pmol/l; GFR 60-89: 488 pmol/l; GFR < 60: 953 pmol/l; P < 0.0001). In post-hoc pairwise comparisons, all 3 groups were significantly different from each other ( Figure 1 ).
After adjustment for ethnicity, sex, age, presence of hypertension, diabetes mellitus, beta-blocker use, aspirin, angiotensin converting enzyme inhibitor use, furosemide use, and warfarin use, these differences persisted (GFR ≥ 90: 314 pmol/l; GFR 60-89: 414 pmol/l; GFR < 60: 770 pmol/l; P < 0.0001).
In post-hoc pairwise comparisons, subjects with at least moderate renal function (eGFR < 60 ml/min) demonstrated significantly greater levels of dp-ucMGP compared to both subjects with mild renal dysfunction and those with normal renal function. No significant difference was found between subjects with normal renal function and those with mild renal dysfunction in this adjusted comparison ( Figure 1 ).
Relationship between dp-ucMGP and CF-PWV Figure 2 demonstrates the results of a multivariable linear regression in which the independent correlates of CF-PWV were assessed. In this multivariable model, dp-ucMGP was a significant independent predictor of CF-PWV (standardized β = 0.21; 95% CI = 0.03-0.38; P = 0.019). In this model, age (standardized β = 0.47; 95% CI = 0.32-0.63; P < 0.0001) and mean arterial pressure (standardized β = 0.24; 95% CI = 0.10-0.38; P = 0.001) were also significant independent predictors of CF-PWV. Figure 3 shows the results of formal mediation analyses in which the direct and indirect (dp-ucMGP-mediated) effects of eGFR on CF-PWV were examined. In this model, eGFR demonstrated a significant total effect on CF-PWV (standardized β = −0.18; P = 0.013). There was a significant effect of eGFR on dp-ucMGP (standardized β = −0.52; P = 0.001), as well as a significant effect of dp-ucMGP on CF-PWV (standardized β = 0.31; P < 0.0001). The direct effect of eGFR on CF-PWV, however, was nonsignificant (standardized β = −0.027; P = 0.80), whereas its indirect (dp-ucMGP dependent) effect was significant (standardized β = −0.16; P = 0.005).
Dp-ucMGP, eGFR, and CF-PWV: mediation analyses
Relationship between dp-ucMGP and carotid-radial PWV In unadjusted analyses, carotid-radial PWV was negatively associated with carotid-radial PWV (standardized β = −0.21; 95% CI = −0.39 to 0.02; P = 0.03). However, after adjustment for age, sex, race, the presence of hypertension, diabetes mellitus, eGFR, mean arterial pressure, heart rate, serum magnesium, phosphorus, and calcium, dp-ucMGP was not independently associated with CR-PWV (standardized β = 0.18; 95% CI = −0.39 to 0.04; P = 0.11).
Sensitivity analysis
We performed a sensitivity analysis among subjects who were not taking warfarin. In this analysis, observed trends Table 2 . Unadjusted and adjusted comparisons of dp-ucMGP levels in subjects stratified according to eGFR Abbreviations: CI, confidence interval; dp-ucMGP, dephospho-uncarboxylated MGP; eGFR, estimated glomerular filtration rate. a Post-hoc P < 0.05, groups 1 vs. 3. b Post-hoc P < 0.05, groups 1 vs. 2. c Post-hoc P < 0.05, groups 2 vs. 3.
Figure 1. (A)
Unadjusted comparison of dp-ucMGP levels between subjects with normal renal function, mildly reduced eGFR, and at least moderately reduced eGFR; (B) Comparison adjusted for ethnicity, sex, age, presence of hypertension, diabetes mellitus, beta-blocker use, aspirin, angiotensin converting enzyme inhibitor use, furosemide use, and warfarin use.
were very similar to the overall analysis regarding differences in dp-ucMGP levels between the 3 eGFR strata in unadjusted and multivariable analyses. Similarly, the results of mediation analyses in this subpopulation regarding the relationship between eGFR, dp-ucMGP, and CF-PWV were similar, demonstrating a significant effect of eGFR on dp-ucMGP (standardized β = −0.365; P < 0.0001), a significant effect of dp-ucMGP on CF-PWV (standardized β = 0.42; P < 0.0001), a significant dp-ucMGP-mediated effect of eGFR on CF-PWV (standardized β = −0.154; P < 0.0001), and a nonsignificant direct effect of eGFR on CF-PWV. Mediation models examining the direct and indirect (dp-ucMGP-mediated) effects of eGFR on carotid-femoral pulse wave velocity (CF-PWV). Path a (red arrow) represents the effect of eGFR on dp-ucMGP. Path b (red arrow with blue head) represents the effect of dp-ucMGP on CF-PWV. Path c ′ (red line) represents the "direct" (dp-ucMGP-independent) effect of eGFR on CF-PWV. The indirect effect of eGFR on CF-PWV (i.e., the effect mediated by dp-ucMGP) is shown as the white arrow within the blue circle. **Significant path with P < 0.01; ***significant path with P < 0.001.
DISCUSSION
In this study, we investigated the association between plasma levels of dp-ucMGP, a marker of vitamin K status, renal function, and arterial stiffness. We found that lower kidney function is independently associated with greater levels of plasma dp-ucMGP. In addition, we demonstrated that greater levels of dp-ucMGP are independently associated with increased CF-PWV (a measure of large artery stiffness) but not with carotid-radial PWV (a measure of muscular artery stiffness). We further demonstrate that dp-ucMGP levels mediate a significant relationship between eGFR and higher CF-PWV, whereas no significant dp-ucMGP-independent relationship was present.
A previous study demonstrated increased levels of dpucMGP in patients with end-stage kidney disease, but limited data exist in earlier stages of CKD. 10 In a previous study in which CKD subjects with a mean eGFR indicative of moderate CKD were included, lower levels of uncarboxylated MGP were reported to be associated with a lower eGFR. 11 We hereby demonstrate that a reduced eGFR is associated with a higher level of dp-ucMGP. Since ucMGP is the intermediate product between the precursor (dp-ucMGP) and carboxylated active MGP, its levels do not provide a clear indication of either the level of dp-ucMGP or the level of active MGP. Therefore, nonphosphorylated, noncarboxylated MGP (dpucMGP) is now thought to be a better indicator of vascular vitamin K status, as compared with other components of the MGP system. Our findings are also consistent with a recent report that demonstrated that dp-ucMGP levels were associated with proteinuria, inversely related to eGFR and significantly higher in CKD stage 5 patients than those in stage 4. 12 In the current study, we also studied the relationship between dp-ucMGP and CF-PWV (a measure of large artery stiffness) and carotid-radial PWV (a measure of mediumsized, muscular artery stiffness). We demonstrated that greater levels of dp-ucMGP were associated with higher CF-PWV but not with carotid-radial PWV. The relationship with CF-PWV persisted after adjustment for multiple confounders in multivariate analysis. Our findings are consistent with accumulating evidence regarding the important role of active MGP as an inhibitor of vascular calcification. [13] [14] [15] Two recent reports demonstrated a relationship between dp-ucMGP and CF-PWV in a general population sample 2 and in a population of patients with type 2 diabetes mellitus. 16 However, the relationship between vitamin K status and CF-PWV in early CKD has not been previously reported. Previous studies have demonstrated that higher levels of plasma dp-ucMGP are associated with the severity of aortic calcification in patients with CKD. 17, 18 However, dp-ucMGP levels were not found to be associated with CF-PWV in a previous study in advanced CKD (dialysis patients). 19 Only one previous study assessed the relationship between dp-ucMGP and PWV in stages 3-5 CKD. 18 In this study, dp-ucMGP was not significantly related to cardio-ankle PWV (which includes the aortic path and a long muscular segment). Our study separately examined large artery (CF-PWV) and muscular artery (carotid-radial) stiffness while including both subjects with eGFR levels higher than 60 ml/min/1.73 m 2 and those with eGFR levels indicative of CKD stages 3-5.
Our study not only provides evidence that dp-ucMGP is independently correlated with CF-PWV but also that this relationship is selective for large artery stiffness, without an independent relationship with muscular artery stiffness. It is likely that muscular artery PWV confounded the relationship with large artery stiffness in the previous study. The factors underlying a selective association between dp-ucMGP and large artery stiffness are probably related to the wellknown differences in the pathophysiologic determinants of stiffening of elastic arteries vs. muscular arteries. We note that the former, and not the latter, is independently associated with cardiovascular risk. 5 Interestingly, in patients with pre-existing cardiovascular disease, circulating dp-ucMGP is associated with mortality and added cardiovascular risk. 20, 21 It remains to be determined whether dp-ucMGP is related to incident risk independently of CF-PWV.
Using formal statistical mediation analysis, we demonstrate, for the first time, that dp-ucMGP explains the vast majority of the underlying relationship between eGFR and CF-PWV, even after adjustment for confounders. These findings are consistent with paradigm that a poor vitamin K status, which has recently been shown to be caused by CKD in an animal model, 4 leads to greater arterial calcification and stiffening. However, there may be bidirectional relationships. In a recent longitudinal study of Flemish subjects, higher circulating dp-ucMGP predicted a greater decline in kidney function. 22 Given that large artery stiffness contributes to systolic hypertension, which in turn can promote CKD progression, it is possible that abnormal vitamin K status mediates a vicious circle of arterial calcification/stiffening and worsening CKD. Whether vitamin K supplementation can interrupt this process, and whether it leads to clinical benefit in early CKD, remains to be tested in properly designed clinical trials. Vitamin K2 supplementation has been shown to reduce dp-ucMGP levels, indicating that it exerts a positive effect on MGP maturation/carboxylation, consistent with its known biologic role. 12, 23 An interesting related issue is that warfarin, a commonly prescribed anticoagulant in CKD patients, inhibits vitamin K reductase, affecting MGP maturation, increasing dpucMGP levels, which may contribute to vascular calcification.
Our study should be interpreted in the context of its strengths and limitations. Strengths of our study include the inclusion of a multiethnic population of patients across the spectrum of early eGFR values, the separate assessment of large artery and muscular artery stiffness, and the use of formal mediation analyses to interrogate underlying statistical relationships. We used high-fidelity carotid and femoral tonometry for measurements of CF-PWV, which is considered the gold-standard noninvasive approach for the noninvasive assessment of large artery stiffness. Our study also has some limitations. Consistent with the demographics of patients in a VA Medical Center, our sample was composed predominantly of males. There was a relatively small number of patients with advanced CKD, and thus, our study should not be considered to address dp-ucMGP levels in advanced CKD. We did not measure vascular calcification, which would have required dedicated imaging modalities (such as computed tomography scans). Finally, this was a crosssectional investigation which can only provide evidence of associations rather than causal inferences.
In conclusion, lower kidney function is independently associated with greater levels of plasma dp-ucMGP, a marker of poor vitamin K status. In turn, greater levels of dpucMGP are independently associated with large artery stiffness but not muscular artery stiffness. Finally, dp-ucMGP levels largely explain the association between a lower CKD and a greater PWV, without evidence of a dp-ucMGP-independent relationship. Our findings should stimulate further studies on dp-ucMGP and trials with vitamin K supplementation in early CKD, to assess whether this intervention can ameliorate the marked, progressive large artery stiffening that occurs with progression to end-stage renal disease.
